- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis shows that the financial resources of AstraZeneca Transforming How New Medicines Flow to Patients are highly valuable as these help in investing into external opportunities that arise. These also help AstraZeneca Transforming How New Medicines Flow to Patients in combating external threats.
- According to the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis shows that AstraZeneca Transforming How New Medicines Flow to Patients's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of AstraZeneca Transforming How New Medicines Flow to Patients's products.
- According to the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for AstraZeneca Transforming How New Medicines Flow to Patients. These patents also provide AstraZeneca Transforming How New Medicines Flow to Patients with licensing revenue when it licenses these patents out to other manufacturers.
- The AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis shows that AstraZeneca Transforming How New Medicines Flow to Patients’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for AstraZeneca Transforming How New Medicines Flow to Patients. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis shows that the research and development at AstraZeneca Transforming How New Medicines Flow to Patients is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for AstraZeneca Transforming How New Medicines Flow to Patients. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of AstraZeneca Transforming How New Medicines Flow to Patients are found to be rare according to the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as AstraZeneca Transforming How New Medicines Flow to Patients and inhibit competitive advantage. This means that the local food products result in competitive parity for AstraZeneca Transforming How New Medicines Flow to Patients. As this resource is valuable, AstraZeneca Transforming How New Medicines Flow to Patients can still make use of this resource.
- The employees of AstraZeneca Transforming How New Medicines Flow to Patients are a rare resource as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of AstraZeneca Transforming How New Medicines Flow to Patients are a rare resource as identified by the AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows AstraZeneca Transforming How New Medicines Flow to Patients to use them without interference from the competition.
- The distribution network of AstraZeneca Transforming How New Medicines Flow to Patients is a rare resource as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of AstraZeneca Transforming How New Medicines Flow to Patients. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of AstraZeneca Transforming How New Medicines Flow to Patients are costly to imitate as identified by the AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by AstraZeneca Transforming How New Medicines Flow to Patients provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of AstraZeneca Transforming How New Medicines Flow to Patients are also not costly to imitate as identified by the AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from AstraZeneca Transforming How New Medicines Flow to Patients by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of AstraZeneca Transforming How New Medicines Flow to Patients a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of AstraZeneca Transforming How New Medicines Flow to Patients are very difficult to imitate as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of AstraZeneca Transforming How New Medicines Flow to Patients is also very costly to imitate by competition as identified by the AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. This has been developed over the years gradually by AstraZeneca Transforming How New Medicines Flow to Patients. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of AstraZeneca Transforming How New Medicines Flow to Patients are organised to capture value as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for AstraZeneca Transforming How New Medicines Flow to Patients.
- The Patents of AstraZeneca Transforming How New Medicines Flow to Patients are not well organised as identified by the AstraZeneca Transforming How New Medicines Flow to Patients VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if AstraZeneca Transforming How New Medicines Flow to Patients starts selling patented products before the patents expire.
- The distribution network of AstraZeneca Transforming How New Medicines Flow to Patients is organised as identified by the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients. AstraZeneca Transforming How New Medicines Flow to Patients uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for AstraZeneca Transforming How New Medicines Flow to Patients.
From the VRIO Analysis of AstraZeneca Transforming How New Medicines Flow to Patients, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of AstraZeneca Transforming How New Medicines Flow to Patients is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Niao-ka
5.0
I guess the expert that I was assigned with is a magician for the reason that it's impossible to write a 10-page assignment without an error. Actually, I commit mistakes even if I write ten sentences.
Sophie Daniel
5.0
Visited many services but this one is the most adequate in the manner of the uniqueness of papers. Thanks for giving me lots of discounts!
Chloe Josh
5.0
I had certain doubts before using this service. Though, all are eliminated because this service did its duties well.
Else Ottin
5.0
The quality of the assignment was exceptional and I obtained a very good CGPA. No doubt, you guys deserve appreciation. I’m also happily going to finish my degree. Highly recommended!
Next Articles
- Selling A New Old Idea: Virginia Business Ventures Vrio Analysis
- The Product Manager Vrio Analysis
- Hypothesis Driven Entrepreneurship: The Lean Startup Vrio Analysis
- Best Buy: Merging Lean Sigma With Innovation Vrio Analysis
- Customer Discovery And Validation For Entrepreneurs Vrio Analysis
- Patricia Gottesman At Crimson Hexagon Vrio Analysis
- Driving Profitable Growth At US Auto Parts Vrio Analysis
- Designing For Growth: A Tool Kit For Managers Vrio Analysis
- St. Mary Maternity Hospital: Introduction To SPSS And Statistical Analysis Vrio Analysis
- Alumni Giving Vrio Analysis
Previous Articles
- Sustainability: How Stakeholder Perceptions Differ From Corporate Reality Vrio Analysis
- AVA.ph: Growing A Filipino E Commerce Company Vrio Analysis
- Pixability: Bettina's Board Walk Vrio Analysis
- Lenovo: Disruption Of The PC Industry Vrio Analysis
- Ministry Of Supply: Will Professionals Demand Its Performance? Vrio Analysis
- Peixe Urbano (B) From Founder To Turnaround CEO Vrio Analysis
- Google Glass Vrio Analysis
- Bloomberg Sports Vrio Analysis
- Haute Hunte: Pursuing The Big Trophy Vrio Analysis
- Social Media: A Tool For Open Innovation Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!